BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...efficacy data for a protein degrader; Kymera Therapeutics Inc. (NASDAQ:KYMR), C4 Therapeutics Inc. (NASDAQ:CCCC) and Nurix Therapeutics Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...Inc. (NASDAQ:KYMR), C4 Therapeutics Inc. (NASDAQ:CCCC) and Nurix Therapeutics Inc....
BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

...to enter the clinic this year. Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), Kymera Therapeutics Inc. (NASDAQ:KYMR) and Nurix Therapeutics Inc....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Companies including Arvinas, Kymera Therapeutics Inc. (NASDAQ:KYMR), Nurix Therapeutics Inc....
...covalent ligands that bind undisclosed new E3 ligases.Nurix...
...autoimmune or inflammatory diseases, and C4 and Nurix...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...66% in its first trading day and remains about 50% above its IPO price, while Nurix Therapeutics Inc....
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...from their IPO price. The third company, Nurix Therapeutics Inc....
...biotech shares rights to the program with Sanofi.Nurix...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...has a placeholder figure of $100 million. Another preclinical company in the protein degradation space, Nurix Therapeutics Inc....
...IRAK4 - Interleukin-1 receptor-associated kinase 4 TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Kymera Therapeutics Inc. Nurix Therapeutics Inc. Freeline...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...Inc. (NASDAQ:NKTX) raised $289.8 million in early July, while on July 24 protein degradation company Nurix Therapeutics Inc....
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...see “Nkarta’s IPO” ; “Massive Haul” ). Three of the four -- Annexon Inc. (NASDAQ:ANNX), Nurix Therapeutics Inc....
...offering; Clarus and New Enterprise Associates each held nearly 12% (see “Annexon Joins Queue” ). Nurix...
...million. The company had initially proposed to sell 8.8 million shares at $16-$18. San Francisco-based Nurix...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...companies in the queue proposed terms for their listings, including Annexon Inc., iTeos Therapeutics Inc., Nurix Therapeutics Inc....
...Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon Biosciences Inc. iTeos Therapeutics S.A. Inozyme Pharma Inc. Nurix Therapeutics Inc. IPO initial...
Items per page:
1 - 10 of 35
BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...efficacy data for a protein degrader; Kymera Therapeutics Inc. (NASDAQ:KYMR), C4 Therapeutics Inc. (NASDAQ:CCCC) and Nurix Therapeutics Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...Inc. (NASDAQ:KYMR), C4 Therapeutics Inc. (NASDAQ:CCCC) and Nurix Therapeutics Inc....
BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

...to enter the clinic this year. Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), Kymera Therapeutics Inc. (NASDAQ:KYMR) and Nurix Therapeutics Inc....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Companies including Arvinas, Kymera Therapeutics Inc. (NASDAQ:KYMR), Nurix Therapeutics Inc....
...covalent ligands that bind undisclosed new E3 ligases.Nurix...
...autoimmune or inflammatory diseases, and C4 and Nurix...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...66% in its first trading day and remains about 50% above its IPO price, while Nurix Therapeutics Inc....
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...from their IPO price. The third company, Nurix Therapeutics Inc....
...biotech shares rights to the program with Sanofi.Nurix...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...has a placeholder figure of $100 million. Another preclinical company in the protein degradation space, Nurix Therapeutics Inc....
...IRAK4 - Interleukin-1 receptor-associated kinase 4 TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Kymera Therapeutics Inc. Nurix Therapeutics Inc. Freeline...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...Inc. (NASDAQ:NKTX) raised $289.8 million in early July, while on July 24 protein degradation company Nurix Therapeutics Inc....
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...see “Nkarta’s IPO” ; “Massive Haul” ). Three of the four -- Annexon Inc. (NASDAQ:ANNX), Nurix Therapeutics Inc....
...offering; Clarus and New Enterprise Associates each held nearly 12% (see “Annexon Joins Queue” ). Nurix...
...million. The company had initially proposed to sell 8.8 million shares at $16-$18. San Francisco-based Nurix...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...companies in the queue proposed terms for their listings, including Annexon Inc., iTeos Therapeutics Inc., Nurix Therapeutics Inc....
...Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon Biosciences Inc. iTeos Therapeutics S.A. Inozyme Pharma Inc. Nurix Therapeutics Inc. IPO initial...
Items per page:
1 - 10 of 35